NanoVation Therapeutics is a pioneer in the design and creation of lipid nanoparticles (LNPs) for nucleic acid delivery. The company’s LNP technologies aim to overcome the limitations of existing nucleic acid delivery approaches, including the ability to target tissues outside the liver (extrahepatic delivery).

NanoVation’s lead technology is its proprietary long-circulating LNP (lcLNP™) platform, which enables functional nucleic acid delivery to extrahepatic cell types and has demonstrated an improved therapeutic index in preclinical studies.

NanoVation partners with leading pharmaceutical and biotech companies develop genetic medicines for previously untreatable diseases.
NTx is delivering tomorrow's genetic medicines, today.

For more information, please visit nanovationtx.com.


Biotechnology

Health Care

Nanotechnology

Pharmaceutical

Therapeutics

NanoVation Therapeutics™

NanoVation Therapeutics™'s headquarters in Vancouver, Canada

Description

People (2)

David Broemeling

Allison Enjetti

Jobs